| Literature DB >> 30137274 |
Pankaj Garg1, Rob J van der Geest2, Peter P Swoboda1, Saul Crandon1, Graham J Fent1, James R J Foley1, Laura E Dobson1, Tarique Al Musa1, Sebastian Onciul1, Sethumadhavan Vijayan1, Pei G Chew1, Louise A E Brown1, Malenka Bissell1, Mariëlla E C J Hassell3, Robin Nijveldt3, Mohammed S M Elbaz2, Jos J M Westenberg2, Erica Dall'Armellina1, John P Greenwood1, Sven Plein1.
Abstract
Aims: The main aim of this study was to characterize changes in the left ventricular (LV) blood flow kinetic energy (KE) using four-dimensional (4D) flow cardiovascular magnetic resonance imaging (CMR) in patients with myocardial infarction (MI) with/without LV thrombus (LVT). Methods and results: This is a prospective cohort study of 108 subjects [controls = 40, MI patients without LVT (LVT- = 36), and MI patients with LVT (LVT+ = 32)]. All underwent CMR including whole-heart 4D flow. LV blood flow KE wall calculated using the formula: KE=12 ρblood . Vvoxel . v2, where ρ = density, V = volume, v = velocity, and was indexed to LV end-diastolic volume. Patient with MI had significantly lower LV KE components than controls (P < 0.05). LVT+ and LVT- patients had comparable infarct size and apical regional wall motion score (P > 0.05). The relative drop in A-wave KE from mid-ventricle to apex and the proportion of in-plane KE were higher in patients with LVT+ compared with LVT- (87 ± 9% vs. 78 ± 14%, P = 0.02; 40 ± 5% vs. 36 ± 7%, P = 0.04, respectively). The time difference of peak E-wave KE demonstrated a significant rise between the two groups (LVT-: 38 ± 38 ms vs. LVT+: 62 ± 56 ms, P = 0.04). In logistic-regression, the relative drop in A-wave KE (beta = 11.5, P = 0.002) demonstrated the strongest association with LVT.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30137274 PMCID: PMC6302263 DOI: 10.1093/ehjci/jey121
Source DB: PubMed Journal: Eur Heart J Cardiovasc Imaging ISSN: 2047-2404 Impact factor: 6.875
Study demographics (study population = 108)
| Younger controls ( | Age-matched controls ( | LVT− ( | LVT+ ( | ||||
|---|---|---|---|---|---|---|---|
| Baseline characteristics | |||||||
| Age (years) | 30 ± 10 | 57 ± 7 | 60 ± 9 | 61 ± 13 | <0.01 | 0.7 | 1 |
| Sex (female) | 7 | 8 | 8 | 3 | 0.2 | 0.3 | 0.4 |
| Body surface area (m²) | 1.9 ± 0.2 | 1.8 ± 0.2 | 1.9 ± 0.2 | 2 ± 0.2 | 0.2 | 0.03 | 0.67 |
| Smoker | 0 | 0 | 23 | 13 | <0.01 | 0.07 | |
| Hypertension | 0 | 0 | 8 | 9 | 0.02 | 1 | |
| Hypercholesterolaemia | 0 | 0 | 16 | 8 | <0.01 | 0.14 | |
| Diabetes | 0 | 0 | 2 | 8 | 0.48 | 0.01 | |
| Baseline clinical parameters | |||||||
| Systolic BP (mmHg) | 131 ± 34 | 137 ± 16 | 0.5 | ||||
| Heart rate (b.p.m.) | 64 ± 7 | 65 ± 15 | 65.5 ± 9 | 66 ± 12 | 1 | 0.10 | 0.3 |
| KC 1 | 33 | 25 | 0.12 | ||||
| KC 2 | 3 | 7 | 0.12 | ||||
| Medical therapy at the time of recruitment | |||||||
| ACE-inhibitor | 35 | 23 | 0.11 | ||||
| HMG-CoA reductase inhibitors | 35 | 20 | 0.07 | ||||
| β-blockers | 35 | 23 | 0.11 | ||||
| Aspirin | 35 | 20 | 0.07 | ||||
| Anti-coagulation | 1 | 4 | 0.04 | ||||
| Blood results | |||||||
| Haemoglobin (g/dL) | 144 ± 14 | 141 ± 12 | 0.99 | ||||
| eGFR | 83.7 ± 9 | 77 ± 17 | 0.08 | ||||
| C-reactive protein (mg/L) | 36 ± 38 | 24 ± 22 | 0.55 | ||||
| HBA1c (mmol/mol) | 41.5 ± 11 | 47 ± 18 | 0.28 | ||||
Data are presented as mean ± standard deviation or count (n).
BP, blood pressure; CAD, coronary artery disease; KC, heart failure Killip class.
Younger controls vs. older age-matched to patient controls.
Age-matched controls vs. LVT−.
LVT− vs. LVT+.
Left ventricular baseline volumetric and haemodynamic study
| Younger controls ( | Age-matched controls ( | LVT− ( | LVT+ ( | ||||
|---|---|---|---|---|---|---|---|
| Volumetric assessment | |||||||
| Anterior infarction ( | 22 | 28 | 0.01 | ||||
| Infarct size (% of LV) | 21 ± 14 | 24 ± 12 | 0.6 | ||||
| Apical RWMA score | 3 ± 1 | 4 ± 0.5 | 0.055 | ||||
| Stroke volume (mL) | 105 ± 30 | 93 ± 28 | 77 ± 26 | 75 ± 31 | <0.01 | 0.06 | 0.42 |
| Ejection fraction (%) | 62 ± 7 | 64 ± 5 | 44 ± 11 | 32 ± 17 | 0.13 | <0.01 | <0.01 |
| LVEDVi (mL/m2) | 91 ± 19 | 75 ± 21 | 91 ± 16 | 100 ± 43 | <0.01 | <0.01 | 0.01 |
| LVESVi (mL/m2) | 35 ± 11 | 27 ± 6 | 52 ± 15 | 67 ± 41 | <0.01 | <0.01 | <0.01 |
| LVMi (g/m2) | 52 ± 15 | 49 ± 9 | 56 ± 13 | 68 ± 21 | 0.44 | 0.03 | <0.01 |
| Haemodynamic assessment | |||||||
| E-wave velocity (cm/s) | 59 ± 44 | 48 ± 22 | 26 ± 9 | 27 ± 10 | 0.08 | <0.01 | 0.66 |
| A-wave velocity (cm/s) | 32 ± 19 | 34 ± 13 | 24 ± 8 | 24 ± 8 | 0.65 | <0.01 | 0.21 |
| | 2 ± 0.6 | 1.3 ± 0.4 | 1.3 ± 0.7 | 1.2 ± 0.8 | 0.09 | 0.71 | 0.71 |
| MDT (ms) | 147 ± 35 | 140 ± 26 | 146 ± 30 | 137 ± 42 | 0.7 | 0.4 | 0.81 |
| Mitral regurgitation (mL) | 0 ± 0.01 | 0 ± 0.02 | 3 ± 4 | 4 ± 3 | 0.33 | 0.01 | 0.09 |
Data are presented as median ± interquartile range or count (n). LV measurements are indexed to body surface area.
LVEDVi, left ventricular end-diastolic volume (indexed); LVESVi, left ventricular end-systolic volume (indexed); LVMi, left ventricular mass (indexed); MDT, mitral deceleration time; MV, mitral valve; RWMA, regional-wall motion abnormality score (1 = normal, 2 = hypokinaesia, 3 = akinetic, 4 = diskinetic).
Younger controls vs. older age-matched to patient controls.
Age-matched controls vs. LVT−.
LVT− vs. LVT+.
These peak inflow velocities are average peak velocities for the full mitral annular flow.
Detailed mapping of left ventricular kinetic energy
| Younger controls ( | Age-matched controls ( | LVT− | LVT+ | ||||
|---|---|---|---|---|---|---|---|
| Global LV kinetic energy | |||||||
| LV | 10 ± 4 | 8.3 ± 1.5 | 6.3 ± 2 | 5.6 ± 2 | 0.63 | 0.01 | 0.19 |
| Minimal | 1 ± 0.4 | 0.9 ± 0.5 | 0.7 ± 0.56 | 0.8 ± 0.61 | 0.64 | 0.07 | 0.19 |
| Systolic | 10 ± 3 | 9 ± 4 | 6.6 ± 2 | 6.7 ± 3 | 0.98 | <0.01 | 0.65 |
| Diastolic | 10 ± 4 | 8 ± 2 | 5.9 ± 3 | 5.4 ± 2 | 0.47 | 0.07 | 0.31 |
| Peak E-wave | 25 ± 13 | 22 ± 12 | 12.4 ± 7 | 10.8 ± 8 | 0.01 | <0.01 | 0.54 |
| Peak A-wave | 9 ± 5 | 13 ± 10 | 11 ± 5 | 9.5 ± 5 | 0.01 | 0.15 | 0.08 |
| In-plane KE (%) | 33 ± 10 | 37 ± 6 | 36 ± 7 | 40 ± 5 | 0.27 | 0.82 | 0.02 |
| Relative KE drop from base to apex (%) | |||||||
| E-wave (B→M) | 60 ± 18 | 52 ± 12 | 56 ± 16 | 65 ± 27 | 0.18 | 0.42 | 0.22 |
| A-wave (B→M) | 69 ± 12 | 68 ± 2 | 64 ± 17 | 60 ± 33 | 0.36 | 0.69 | 0.08 |
| E-wave (M→A) | 88 ± 8 | 89 ± 5 | 89 ± 9 | 89 ± 10 | 0.44 | 0.7 | 0.38 |
| A-wave (M→A) | 78 ± 10 | 78 ± 11 | 78 ± 14 | 87 ± 9 | 0.34 | 0.27 | <0.01 |
Data are presented as median ± interquartile range or count (n). Unit of normalized kinetic energy: μJ/mL.
B→M, base to mid-ventricle; KE, kinetic energy; M→A, mid-ventricle to apex.
Younger controls vs. older age-matched to patient controls.
Age-matched controls vs. LVT−.
LVT− vs. LVT+.
KEiEDV variables (μJ/mL).
Logistic regression analysis of variables which influence presence of LVT
| Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|
| Beta | SD | Beta | SD | |||
| DM | −1.8 | 0.8 | 0.03 | 0.14 | ||
| Anterior MI | −1.5 | 0.6 | 0.02 | 0.13 | ||
| Ejection fraction | −0.81 | 0.03 | <0.01 | − | ||
| Distal A-wave KE drop | 8.4 | 2.9 | <0.01 | |||
| In-plane KE | 0.13 | 0.06 | 0.02 | 0.19 | ||
| Time difference | 0.011 | 0.006 | 0.04 | 0.74 | ||
Bold results are highlight independent predictors in the regression model.
DM, diabetes mellitus; KE, kinetic energy; MI, myocardial infarction.